Anti-Bcl-2 Antibody [PD01-41]

HA721235

Anti-Bcl-2 Antibody [PD01-41]

Proteins of the Bcl-2 family are regulators of apoptosis (programmed cell death) localized to membranes of primarily mitochondria, but also to smooth endoplasmic reticulum and nucleolemma. The fine balance between pro- and anti-apoptotic Bcl-2 family members regulates the cell fate in response to many signalling pathways. Altered expression of the proteins may lead to either premature cell death or to inappropriate cell survival promoting neoplastic growth. Bcl-2, Bax and Bcl-X are the most well known proteins in this family. In neoplastic lesions Bcl-2 upregulation may act by suppression of programmed cell death and extension of the tumour cell life span. Bcl-2 overexpression contributes to increased resistance to chemotherapy. However, the prognostic value of Bcl-2 overexpression is dependent on the tumour type, and in some types BCl-2 may even have a tumour suppressor effect. Overexpression of Bcl-2 is common in many types of cancer, including non-Hodgkin's lymphoma and leukaemias, adenocarcinomas (e.g., prostate, colorectum, stomach, and lung), squamous cell carcinoma, small cell carcinoma, neuroblastoma and various sarcomas. Bcl-2 is helpful in distinguishing follicular lymphoma from reactive follicular hyperplasia. Bcl-2 staining can not be used for differential diagnosis between follicular lymphoma and other types of low-grade B-cell lymphomas since most of the latter also express bcl-2. Monocytoid B-cell hyperplasia contrasts with bcl-2 negativity against positive reaction in 80% of the marginal zone lymphomas. Possibly, Bcl-2 may aid in the differential diagnosis of sarcomas. Tonsil is recommendable as positive and negative tissue control for BCL2. A moderate to strong, predominantly cytoplasmic staining reaction should be displayed in virtually all T-cells and B-cells in the mantle zone of the reactive follicles, whereas the majority of the basal squamous epithelial cells, e.g. lining the tonsillar crypts, must show an at least weak staining intensity. Germinal centre T-cells should be distinctively demonstrated, whereas germinal centre B-cells should be negative.

496.5 €

ER1706-47

Anti-Bcl-2 Antibody

Bcl-2 is one among many key regulators of apoptosis, which are essential for proper development, tissue homeostasis, and protection against foreign pathogens. Human Bcl-2 is an anti-apoptotic, membrane-associated oncoprotein that can promote cell survival through protein-protein interactions with other Bcl-2 related family members, such as the death suppressors Bcl-xL, Mcl-1, Bcl-w, and A1 or the death agonists Bax, Bak, Bik, Bad, and Bid. The anti-apoptotic function of Bcl-2 can also be regulated through proteolytic processing and phospho-rylation. Bcl-2 may promote cell survival by interfering with the activation of the cytochrome c/Apaf-1 pathway through stabilization of the mitochondrial membrane. Mutations in the Bcl-2 gene can contribute to cancers where normal physiological cell death mechanisms are compromised by deregulation of the anti-apoptotic influence of Bcl-2.

433.5 €

ER1802-97

Anti-Bcl-2 Antibody

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release.

433.5 €

M1206-4

Anti-Bcl-2 Antibody [F7-1-A1]

Bcl-2 (B-cell lymphoma 2) is the founding member of the Bcl-2 family of apoptosis regulator proteins encoded by the BCL2 gene. It has been implicated in a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukemia, and lung carcinomas, as well as schizophrenia and autoimmunity. It is also thought to be involved in resistance to conventional cancer treatment.

465 €

MBS8108665-01mL

Anti-Bcl-2 Antibody, Rabbit Polyclonal

567.5 €

MBS8108665-5x01mL

Anti-Bcl-2 Antibody, Rabbit Polyclonal

1715 €